Movano Inc. announced the completion of an Institutional Review Board (IRB)-approved blood pressure clinical study, which was conducted on 110 consented participants at the Movano Clinical Lab over a six week period in the fourth quarter of 2021. During the study, participants wore Movano's adjustable full finger ring prototype and its wrist-worn wearable prototype along with a hospital-grade FDA-cleared vital signs monitor as the control. Movano's devices collected pulse pressure waveform data, which will be compared to data from the control device in order to further its signal processing and algorithms. Movano's proprietary integrated circuits in the wrist-worn prototype, which are supported by a radio-frequency technology platform, app and cloud infrastructure, allow Movano to calculate blood pressure, glucose, heart rate, and respiration rate estimates.

The ring prototype also has an optical sensor to estimate SpO2 measurements and an accelerometer to measure steps and calories. Movano also plans to execute its second glucose study with an independent FDA-compliant clinical lab during the first quarter of 2022. Similar to the initial glucose clinical study in December 2020, all subjects are expected to be persons with Type 1 diabetes with varying gender, age, ethnicity and BMI.